Core Viewpoint - On its 30th anniversary, Shuanglu Pharmaceutical is facing a historic turning point, reporting a net loss of approximately 74.07 million yuan for 2024, marking its first annual loss since its listing in 2004 [1][4]. Financial Performance - In 2024, Shuanglu Pharmaceutical achieved an operating revenue of approximately 660 million yuan, a year-on-year decline of 35.15%, with a corresponding net profit of -74.07 million yuan, transitioning from profit to loss [4]. - The company had previously seen net profits exceeding 100 million yuan since 2007, peaking at 695 million yuan in 2014, and fluctuating between 200 million and 500 million yuan from 2020 to 2023 [4]. - In the first quarter of 2024, the company reported an operating revenue of approximately 169 million yuan, down 31.1%, and a net profit of approximately 45.97 million yuan, down 34.46% [4]. Product Sales Decline - Multiple key products experienced significant sales declines in 2024, with the oncology and immune regulation products generating sales of 276 million yuan, accounting for 42.69% of total sales, down 27.69% year-on-year [6]. - The sales of the previously promising product, Lenalidomide, accounted for only 4.89% of the oncology product category, with a staggering year-on-year decline of 77.22% [6][7]. - Other product categories, including anti-infection, trauma repair, and cardiovascular products, also saw sales declines of 48.42%, 30.95%, and 33.92% respectively [7]. Financial Asset Impact - The decline in financial assets, particularly the fair value changes in securities investments, significantly impacted the company's performance, with a total loss of approximately 178 million yuan from its holdings in Fosun Pharma, Shouyao Holdings, and Xinghao Pharma [9]. - The fair value changes for these stocks were -22.94 thousand yuan, -161 million yuan, and -16.14 million yuan respectively, contributing to the overall financial downturn [9]. Future Outlook - The company plans to increase R&D investment and has developed a strong product pipeline in oncology, liver disease, antiviral, metabolic regulation, and cardiovascular fields, while also exploring new areas such as diabetes and ophthalmology [5]. - The chairman expressed optimism that the company will recover its performance, viewing 2025 as a year of both challenges and opportunities [5][10].

山东步长制药股份有限公司 证券代码：603858 证券简称：步长制药 公告编号：2025-061 关于全资子公司经营范围变更的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 山东步长制药股份有限公司（以下简称"公司"）于2025年4月2日发出第五届董事会第十九次会议的通 知，并于2025年4月9日13时以通讯方式召开，会议以同意9票、反对0票、弃权0票的表决结果审议通过 了《关于全资子公司经营范围变更的议案》，公司全资子公司保定天浩制药有限公司（以下简称"保定 天浩"）、陕西步长制药有限公司（以下简称"陕西步长"）因经营管理之需要，拟对经营范围进行变 更。具体情况如下： 一、变更情况 （一）保定天浩 截至2023年12月31日，资产总额48,863.12万元，负债总额31,996.87万元，净资产16,866.25万元，2023年 度实现营业收入121,474.02万元，净利润15,636.25万元。（上述数据经审计） 截至2024年9月30日，资产总额43,242.74万元，负债总额28,880.48万元，净资产14, ...